Globus Medical stock has delivered a 49.1% return over the past year, yet its current valuation checks still lean on the cheap side, which raises the question of whether the market is fully pricing in the company’s prospects.

• Globus Medical is up 49.1% over the past year, which puts recent buyers sitting on sizeable gains that may already reflect improving expectations.
• The upcoming earnings release and investor call in early August can shape views on the company’s growth runway. At the same time, any sign of pressure on procedure volumes or margins may weigh on how much investors are willing to pay for the stock.
• The company screens as undervalued across the broader checks, with a strong valuation profile on 6 out of 6 measures. This suggests the current price still looks conservative relative to those metrics.

The issue now is whether Globus Medical’s share price already reflects those positives or if there is still a reasonable margin between today’s market value and what the fundamentals support.

Does Globus Medical Look Undervalued on Earnings?

The P/E ratio suits Globus Medical because earnings are a key anchor for many investors in the Medical Equipment space. Globus Medical currently trades around 18.6x earnings, which is well below the Medical Equipment industry average of about 29.1x and the peer group average of roughly 41.2x. That gap means the market is valuing each dollar of Globus Medical earnings at a lower level than many similar companies.

The tailored fair P/E multiple for Globus Medical is estimated at about 26.4x, based on factors such as its industry, business profile and risk. This sits between the current P/E and the broader peer averages, which indicates the stock is pricing in a discount that appears wider than that model suggests. Despite the upcoming Q2 2026 earnings release and conference call on 6 August drawing attention to the company, the present P/E still sits below both the fair multiple and the typical peer level.

On the P/E multiple alone, Globus Medical stock appears undervalued compared with both its tailored fair ratio and sector peers.

The Globus Medical Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Globus Medical pick up where the valuation puzzle leaves off and explain what would need to be true about Globus Medical's future growth, margins and earnings for the stock to be worth materially more or less than today’s price, based on community views on its Community page. Rather than relying on a single multiple or model output, each narrative lays out its own set of assumptions so you can compare them with actual results as they are reported.

One of the top community narratives on Globus Medical: 25% undervalued

"A robotic ecosystem is viewed as increasingly driving durable implant pull through, which, alongside mid 30s EBITDA margins, supports the case for resilient profitability..."

Do you think there's more to the story for Globus Medical? Head over to our Community to see what others are saying!

The Bottom Line

Globus Medical screens as undervalued on traditional earnings multiples, and that view is supported by its stronger overall valuation checks. The key question is whether the current discount persists or closes over time if the company’s fundamentals continue to line up with those peer comparisons. For buyers and holders, the crux is whether Globus Medical can sustain the earnings profile that justifies a higher P/E without running into pressure on procedure volumes or margins that keeps the stock on a lower multiple.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.